Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response

Treating obesity may directly improve psoriatic arthritis outcomes, according to Phase 3b data released Wednesday by Eli Lilly. In the TOGETHER-PsA trial, patients receiving both Zepbound (tirzepatide) and Taltz (ixekizumab) showed a 64% relative improvement in arthritis disease activity compared to those on Taltz alone. The findings suggest obesity treatment directly improves psoriatic arthritis disease… The post Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response appeared first on Drug Discovery and Development.

Continue reading →